tbuckley/cabot-search huggingface dataset:
The Last (Randomized) Word on Screening for Abdominal Aortic Aneurysms
Authors: Frank A. Lederle
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Monitoring of Serum Hepcidin-25 in Multicentric Castleman’s Disease Patients Treated with Tocilizumab, an Anti-Interleukin-6 Receptor Antibody.
Authors: Hiroshi Kawabata, Naohisa Tomosugi, Junya Kanda, Chisaki Mizumoto, Yasuhiro Tanaka, Tatsuo Ichinohe, Norimitsu Kadowaki, Kazuyuki Yoshizaki, Takayuki Ishikawa, Takashi Uchiyama
Journal: Blood (2007)
Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.
Authors: Rajasubramaniam Shanmugam, Annique Wilson-Weekes, Hamid Sayar, Attaya Suvannasankha, Angelo A. Cardoso, Katie J Sargent, Larry D. Cripe, Dhananjaya V Kalvakolanu, H. Scott Boswell
Journal: Blood (2009)
Salvaged Cord Blood Transplantation For 19 Patients With Progressive Hematologic Malignancies
Authors: Sun Zimin, Yao Wen, Zheng Changcheng, Tong Juan, Liu Huilan, Geng Liangquan, Baolin Tang, Zhu Xiaoyu, Song Kaidi, Kaiyang Ding
Journal: Blood (2013)
Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study
Authors: Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Dolores Hernandez, M Jesús Blanchard, Javier De La Rubia, Miquel Granell, Juan Besalduch, Luis Palomera, Yolanda Gonzalez, M Asunción Echebeste, Joaquín Díaz-Mediavilla, Miguel T Hernandez, Felipe de Arriba, Norma Carmen Gutierrez, M Luisa Martín-Ramos, M Teresa Cibeira, Maria Victoria Mateos, Joaquin Martinez-Lopez, Adrian Alegre, Juan José Lahuerta, Jesus F. San Miguel, Joan Blade
Journal: Blood (2014)
Sunitinib in patients with refractory NSCLC: Primary results from China.
Authors: P. Gu, B. Han, J. Shen, A. Gu, J. L. Yan, H. Wang
Journal: Journal of Clinical Oncology (2010)

e18145 Background: Sunitinib, a small molecule, is a multitargeted receptor kinase inhibitor which targets the vascular endothelial growth factor receptor and platelet-derived growth factor receptor as well as several others. Several clinical trial results have already demonstrated the therapeutic potential of this agent in renal cell carcinoma and gastrointestinal stromal tumor, however, only few studies were conducted to investigate the effectiveness of the use of sunitinib in refractory NSCLC. We reported a case series of patients with previously treated, refractory non-small cell lung cancer and evaluated the clinical activity and tolerability of sunitinib. Methods: Patients with stage IIIb or IV NSCLC for whom platinum-based chemotherapy had failed received sunitinib at a dose of 37.5 mg orally once daily combination with or without standard agents or regimens currently used in the NSCLC. Results: We illustrated 24 refractory NSCLC patients who received sunitinib treatment. Two patients were treated with pemetrexed besides sunitinib, two other patients were treated sunitinib in combination with gemcitabine and gefitinib respectively. Other 20 patients received sunitinib as a single agent. The starting dose of sunitinib was 37.5 mg/d. eight patients who received sunitinib achieved a confirmed objective response. The response rate was 33.3% (8/24). Seven patients showed stable disease. Disease control rate is 62.5% (15/24). Night patients showed progressive disease. PFS ranged from 4 weeks to 18 weeks. mPFS for this study is 4 moths. 1 year survival rate is still follow up. The most commonly AEs (grade 3-4) included fatigue/asthenia (45.8%, 11/24), dry skin (25%, 5/24), and hand-foot syndrome 29.1% (7/24). Other AEs (grade 3-4) were thrombocytopenia, anemia and diarrhea. Conclusions: Sunitinib, as a single agent or in combination with chemotherapy, was well generally tolerated and showed substantial activity in refractory lung cancer. High-quality prospective studies are needed to be conducted. No significant financial relationships to disclose.
Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis
Authors: S. Dhami, H. Zaman, E.-M. Varga, G. J. Sturm, A. Muraro, C. A. Akdis, D. Antolín-Amérigo, M. B. Bilò, D. Bokanovic, M. A. Calderon, E. Cichocka-Jarosz, J. N. G. Oude Elberink, R. Gawlik, T. Jakob, M. Kosnik, J. Lange, E. Mingomataj, D. I. Mitsias, H. Mosbech, M. Ollert, O. Pfaar, C. Pitsios, V. Pravettoni, G. Roberts, F. Ruëff, B. A. Sin, M. Asaria, G. Netuveli, A. Sheikh
Journal: Allergy (2016)

The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the management of insect venom allergy. To inform this process, we sought to assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy.We undertook a systematic review, which involved searching 15 international biomedical databases for published and unpublished evidence. Studies were independently screened and critically appraised using established instruments. Data were descriptively summarized and, where possible, meta-analysed.Our searches identified a total of 16 950 potentially eligible studies; of which, 17 satisfied our inclusion criteria. The available evidence was limited both in volume and in quality, but suggested that venom immunotherapy (VIT) could substantially reduce the risk of subsequent severe systemic sting reactions (OR = 0.08, 95% CI 0.03-0.26); meta-analysis showed that it also improved disease-specific quality of life (risk difference = 1.41, 95% CI 1.04-1.79). Adverse effects were experienced in both the build-up and maintenance phases, but most were mild with no fatalities being reported. The very limited evidence found on modelling cost-effectiveness suggested that VIT was likely to be cost-effective in those at high risk of repeated systemic sting reactions and/or impaired quality of life.The limited available evidence suggested that VIT is effective in reducing severe subsequent systemic sting reactions and in improving disease-specific quality of life. VIT proved to be safe and no fatalities were recorded in the studies included in this review. The cost-effectiveness of VIT needs to be established.
DNA Vaccine Protects Monkeys Against Zika Virus Infection
Authors: Tracy Hampton
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance
Authors: Shiki Takamura, Hideki Yagi, Yoshiyuki Hakata, Chihiro Motozono, Sean R. McMaster, Tomoko Masumoto, Makoto Fujisawa, Tomomi Chikaishi, Junko Komeda, Jun Itoh, Miki Umemura, Ami Kyusai, Michio Tomura, Toshinori Nakayama, David L. Woodland, Jacob E. Kohlmeier, Masaaki Miyazawa
Journal: The Journal of Experimental Medicine (2016)

CD8+ tissue-resident memory T cells (TRM cells) reside permanently in nonlymphoid tissues and provide a first line of protection against invading pathogens. However, the precise localization of CD8+ TRM cells in the lung, which physiologically consists of a markedly scant interstitium compared with other mucosa, remains unclear. In this study, we show that lung CD8+ TRM cells localize predominantly in specific niches created at the site of regeneration after tissue injury, whereas peripheral tissue-circulating CD8+ effector memory T cells (TEM cells) are widely but sparsely distributed in unaffected areas. Although CD69 inhibited sphingosine 1–phosphate receptor 1–mediated egress of CD8+ T cells immediately after their recruitment into lung tissues, such inhibition was not required for the retention of cells in the TRM niches. Furthermore, despite rigid segregation of TEM cells from the TRM niche, prime-pull strategy with cognate antigen enabled the conversion from TEM cells to TRM cells by creating de novo TRM niches. Such damage site–specific localization of CD8+ TRM cells may be important for efficient protection against secondary infections by respiratory pathogens.
Polo-Like Kinase 3, a Novel Regulator of Thrombosis: Positive Regulation of TxA2 Generation, Granular Secretion and Clot Retraction, but Negative Regulation of Integrin Activation
Authors: Meghna Ulhas Naik, Brendan Bachman, John C Kostyak, Wei Dai, Ulhas P Naik
Journal: Blood (2012)
Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center,
Authors: Jae-Cheol Jo, Dok Hyun Yoon, Shin Kim, Seongsoo Jang, Chan-Jeoung Park, Hyun Sook Chi, Chan-Sik Park, Jooryung Huh, Sang-wook Lee, Cheolwon Suh
Journal: Blood (2011)
P1004 : Impact of aerobic exercise in postmenopausal women with Nonalcoholic Fatty Liver Disease: A 24 weeks randomized clinical trial
Authors: R.E. Rezende, S.M. Duarte, J.T. Stefano, L.A. Perandini, T. Dassouki, A.L. Sa-Pinto, H. Roschel, B. Gualano, D.C. Vezozzo, F.J. Carrilho, C.P. Oliveira
Journal: Journal of Hepatology (2015)
Serine Synthesis Helps Hypoxic Cancer Stem Cells Regulate Redox
Authors: Debangshu Samanta, Gregg L. Semenza
Journal: Cancer Research (2016)

Phosphoglycerate dehydrogenase (PHGDH) is the metabolic enzyme responsible for shunting the glycolytic intermediate 3-phosphoglycerate to the serine synthesis pathway. In breast cancer and several other types of cancer, increased PHGDH expression is associated with patient mortality. Early studies focused on the role of PHGDH in promoting cell proliferation in the small percentage of breast cancers with PHGDH gene amplification. However, recent studies have revealed a critical role for PHGDH and downstream enzymes of the serine synthesis pathway and one carbon metabolism in NADPH production and the maintenance of redox homeostasis, which are required for enrichment of breast cancer stem cells in response to hypoxia or chemotherapy. These results provide a mechanism for PHGDH overexpression in breast cancers in which PHGDH is not amplified and have implications for improving the response of triple-negative breast cancers to cytotoxic chemotherapy. Cancer Res; 76(22); 6458-62. ©2016 AACR.
The C-Terminal Zinc Finger of GATA2 Is Necessary for Normalization of Aberrant Myelomonocytic Differentiation Induced by Activating PTPN11 Mutations.
Authors: Zhenyun Yang, Cara S. Voorhorst, Leila Ndong, Fuqin Yin, Takako Kondo, Eri Hashino, Rebecca J. Chan
Journal: Blood (2007)
MNGO-14INCREASED PERIOPERATIVE MORBIDITY AND POOR SURGICAL OUTCOMES IN PATIENTS WITH ASYMPTOMATIC MENINGIOMAS
Authors: Arash Nayeri, Marc Prablek, Philip Brinson, Lola Chambless
Journal: Neuro-Oncology (2015)

INTRODUCTION: Conservative, non-surgical treatment has been argued as the ideal strategy for the management of asymptomatic meningiomas. Nevertheless, a significant number of patients with incidentally discovered and asymptomatic meningiomas continue to undergo operative resections. We sought to analyze the perioperative changes in performance status amongst asymptomatic patients undergoing a meningioma resection. METHODS: We conducted a retrospective cohort study on 265 patients who underwent primary meningioma resection at our institution between 2001-2013. The medical records were used to assign Karnofsky Performance Status (KPS) scores both preoperatively and postoperatively. Latest preoperative clinic or ED presentations were used to estimate the preoperative KPS. Postoperative KPS was assigned at the first outpatient clinic visit. The preoperative assessment was used to categorize patients into either asymptomatic or symptomatic patient groups based on mode of presentation and preoperative symptomatology. Mean KPS changes were compared via student's t-test and Fisher's exact test was utilized to compare differences between categorical groups. RESULTS: Overall, the mean change in KPS after operative resection was +4.30. At time of operation, 19 patients were asymptomatic and 246 patients had tumor-related symptoms. The symptomatic and asymptomatic patient groups experienced an average change of +5.0 and -5.3 in perioperative KPS respectively. 9.3% of patients in the symptomatic group and 57.9% of the patients in the asymptomatic group suffered from perioperative decrease in KPS scores. The differences in the mean changes in KPS and risk of postoperative deterioration between asymptomatic and symptomatic patients were statistically significant (p = 0.003 and p < 0.0001 respectively). CONCLUSIONS: Asymptomatic patients with incidentally discovered meningiomas are at increased risk of short-term perioperative deterioration. These patients may expect a short-term decline in performance status after operative intervention. Further studies are needed to compare the long-term functional outcomes of asymptomatic patients who are operated on versus those managed conservatively.
Lipoprotein (A) and Further Prothrombotic Risk Factors in Women with Unexplained Recurrent Miscarriage- Results of a Multicenter Case-Control Study.
Authors: Ulrike Nowak-Gottl, Barbara Sonntag, Robert Klamroth, Achim Heinecke, Claus Langer, Inge Scharrer, Robert Greb, Manuela Krause
Journal: Blood (2004)
Successful Therapy of a Patient with a Novel STAT1 Gain of Function Mutation and Life-Threatening Cytopenias with Janus Kinase Inhibitor Ruxolitinib
Authors: Katja G. Weinacht, Louis m Charbonnier, Ashley Plant, Troy Torgerson, Sergei Rosenzweig, Thomas Fleisher, Luigi Daniele Notarangelo
Journal: Blood (2015)
Baseline Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Expression in Circulating CD15+/CD30+ Cells Correlate with Very Poor Outcome in Hodgkin Lymphoma
Authors: Rajendra Gharbaran, Andre Goy, Takemi Tanaka, Jongwhan Park, Christopher J Kim, Nafis Hasan, Pritish K. Bhattacharyya, Anthony R Mato, Tatyana Feldman, Andrew L Pecora, K. Stephen Suh
Journal: Blood (2012)
Bisphosphonate Zoledronic Acid (ZOL) Inhibits the Abnormal Proliferation and Differentiation of Juvenile Myelomonocytic Leukemia (JMML) Cells.
Authors: Yoshitoshi Ohtsuka, Atsushi Manabe, Hirohide Kawasaki, Sumiko Watanabe, Yuji Zaike, Daisuke Hasegawa, Toshiyasu Miyazaki, Takakuni Tanizawa, Tatsutoshi Nakahata, Kohichiro Tsuji
Journal: Blood (2004)
HbA1c and the Prediction of Type 2 Diabetes in Children and Adults
Authors: Pavithra Vijayakumar, Robert G. Nelson, Robert L. Hanson, William C. Knowler, Madhumita Sinha
Journal: Diabetes Care (2016)

OBJECTIVE Long-term data validating glycated hemoglobin (HbA1c) in assessing the risk of type 2 diabetes in children are limited. HbA1c, fasting plasma glucose (FPG), and 2-h postload plasma glucose (2hPG) concentrations were measured in a longitudinal study of American Indians to determine their utility in predicting incident diabetes, all of which is thought to be type 2 in this population. RESEARCH DESIGN AND METHODS Incident diabetes (FPG ≥126 mg/dL [7.0 mmol/L], 2hPG ≥200 mg/dL [11.1 mmol/L], HbA1c ≥6.5% [8 mmol/mol], or clinical diagnosis) was determined in 2,095 children without diabetes ages 10–19 years monitored through age 39, and in 2,005 adults ages 20–39 monitored through age 59. Areas under the receiver operating characteristic (ROC) curve for HbA1c, FPG, and 2hPG in predicting diabetes within 10 years were compared. RESULTS During long-term follow-up of children and adolescents who did not initially have diabetes, the incidence rate of subsequent diabetes was fourfold (in boys) as high and more than sevenfold (in girls) as high in those with HbA1c ≥5.7% as in those with HbA1c ≤5.3%—greater rate ratios than experienced by adults in the same HbA1c categories. Analyses of ROCs revealed no significant differences between HbA1c, FPG, and 2hPG in sensitivity and specificity for identifying children and adolescents who later developed diabetes. CONCLUSIONS HbA1c is a useful predictor of diabetes risk in children and can be used to identify prediabetes in children with other type 2 diabetes risk factors with the same predictive value as FPG and 2hPG.
The Effect of Telomerase Antisense on the Differentiation of CD34+ Cells from Bone Marrow to Blood Cells.
Authors: Kyogn Hwa Park, Byung Soo Kim, In Keun Choi, Seok Jin Kim, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim
Journal: Blood (2004)
Transfusion History and Risk of Non-Hodgkin Lymphoma (NHL): an Interlymph Pooled Analysis
Authors: James R Cerhan, Silvia de Sanjosé, Bracci M Paige, John J. Spinelli, Claire M Vajdic, Alain Monnereau, Luigino Dal Maso, Eleanor Kane, Brian C-H Chiu, Leslie Bernstein, Yawei Zhang, Dennis D. Weisenburger, Susan L Slager
Journal: Blood (2014)
CBIO-07COMBINED BH3 AND METABOLIC PROFILING AS A METHOD TO DEFINE THERAPEUTIC RESPONSE AND RESISTANCE IN GRADE IV ASTROCYTOMAS
Authors: Monica Rodriguez Silva, Angel Chinea, Zachary Aberman, Nicole Colwell, Sergio Gonzalez-Arias, Jeremy Chambers
Journal: Neuro-Oncology (2015)

BACKGROUND: Grade IV astrocytomas, formerly known as glioblastoma multiforme (GBM), are the most common primary brain tumors and have the highest mortality. The therapeutic standard for managing this malignancy remains a combination of surgery, chemotherapy, and radiotherapy; however, there is no cure, nor has there been any significant advancement in the clinical approach to GBM since this protocol was established in 2005. This study aims to better understand the molecular and metabolic characteristics of GBM to better define treatment groups and potentially identify new avenues for therapy. This study utilized continuous, commercially-available GBM cell lines U87, U118, A172, and H4, and examined the concentrations of Bcl-2 family proteins on mitochondria and metabolic activity for each of the cell lines. The measures were correlated to temozolamide (TMZ) sensitivity. RESULTS: Western blot analysis of pro-survival and pro-apoptotic Bcl-2 proteins revealed that U118 and U87 expressed high levels of Bcl-2, while A172 had increased Bcl-xL expression. Interestingly, Bcl-2 and Bcl-xL were not detected in H4 cells. Incidentally, pro-apoptotic BH3-only protein levels were increased in H4 and A172 cells. Metabolic analysis of the cell lines revealed that U118 cells were a glutaminolytic, while U87, A172, and H4 were classified as glycolytic. We found that U118 cells were the most resistant followed by U87, A172, and H4, respectively. CONCLUSIONS: We found that Bcl-2 protein profiling was a useful means to determine therapeutic response and resistance. This was enhanced by addingmetabolic stratification, wherein glycolytic cells were shown to be more sensitive TMZ than glutaminolytic cells. We will expand the number of cell lines in our study and increase the cellular profiling to include mitochondrial dynamics. Using this approach, we will produce a method to define GBM responses and outcomes based on the mitochondrial and metabolic context of individual tumors.
Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor
Authors: Mary T Scott, Koorosh Korfi, Paolo Gallipoli, Peter Saffrey, Heather Jorgensen, Michelle Cruz, Ashley Hamilton, Amy Sinclair, Andrew Crossan, Emmanuel Normant, Vidya Balasubramanian, Tessa L. Holyoake, David Vetrie
Journal: Blood (2013)
Molecular inversion probes (MIPs) identify novel copy number changes in pediatric gliomas
Authors: J. D. Schiffman, Y. Wang, S. R. Vandenberg, P. G. Fisher, J. M. Ford, H. Ji, J. G. Hodgson
Journal: Journal of Clinical Oncology (2008)

13006 Background: Childhood brain tumors (CBT) are the most common solid pediatric cancer and the leading cause of pediatric cancer mortality. More than half of all CBTs are gliomas. Despite their high prevalence, little is known about the genetic events that contribute to the development and progression of pediatric gliomas (PGs). In this study, we used Molecular Inversion Probes (MIPs) to identify recurrently amplified or deleted genomic loci in advancing stages of pediatric astrocytomas (PAs). Our results help define the molecular characteristics of PAs, which may lead to the development of novel biomarkers and therapeutic agents. Methods: DNA was extracted from 14 flash- frozen PA biopsies (WHO grade II [n=3, mean age 7 yr]; grade III [n=2, mean age 6 yr]; grade IV [n=9, mean age 12 yr]). DNA was also extracted from 5 adult-gliosis biopsies to use as non-neoplastic controls. The MIP assay was run using 37 ng genomic DNA/sample on a customized Affymetrix 24K Cancer Panel representing oncogenes, tumor suppressor, DNA repair, cell growth, and metabolism genes. Copy number (CN) changes were identified by comparing probe signal intensity between brain tumor and controls. Results: We observed the full spectrum of genomic CN aberrations including regions of single copy gain and loss, homozygous deletions, and high-level focal amplifications. Grade-III and -IV tumors showed more CN alterations relative to grade II tumors. CN changes ranged from < 1000 basepairs to entire chromosome arms. Deleted genes included: DRD3 (3q13), GAP43 (3q13), DHFR (5q14), SOX8 (16p13.3), ADAMTS18 (16q23.1), WWOX (16q23.1). Amplified genes included: PTPN7 (1q32), GPR160 (3q26), PGDFRA (4q12), KIT (4q12), TBXAS1 (7q34), PLAG1 (8q12.1), CHCHD7 (8q12.1), MYC (8q24.1), FOXM1 (12p13), CCND2 (12p13), ERC1 (12p13), WNT5B (12p13), MEGF8 (19q13.2), TUBGCP6 (22q13.33). Several amplifications ranged as high as CN of 80. Conclusions: MIPs can identify both known and novel areas of CN events in PGs using minimal DNA. PGs display increasing molecular CN changes with advancing clinical stages. Areas of amplifications and deletions range from microscopic to macroscopic. Further exploration with larger sample sets (including paraffin-embedded specimens) may increase our understanding of the biology and behavior of PGs. No significant financial relationships to disclose.